BACKGROUND: We conducted a pilot phase II study to evaluate the efficacy and safety of docetaxel and cisplatin as a combination second-line therapy for advanced gastric cancer. PATIENTS AND METHODS: Between 2000 and 2003, 30 patients were enrolled into this study. Chemotherapy consisted of 60 mg/m2 of docetaxel followed by 60 mg/m2 of cisplatin. This regimen was repeated at least three times at 3-week intervals. RESULTS: The overall response rate was 26.7%. The median time to disease progression was 4.5 months. The median survival time was 13 months from the start of the first-line therapy and 6 months from the second-line therapy. With respect to toxicity, the major adverse effect was leukopenia, which reached grades 3-4 in 26.7%. Non-hematological toxicities were usually moderate, and no deaths were attributable to the adverse effects of the drugs. CONCLUSION: This combination therapy was effective as a second-line treatment for advanced gastric cancer with acceptable toxic side-effects.
BACKGROUND: We conducted a pilot phase II study to evaluate the efficacy and safety of docetaxel and cisplatin as a combination second-line therapy for advanced gastric cancer. PATIENTS AND METHODS: Between 2000 and 2003, 30 patients were enrolled into this study. Chemotherapy consisted of 60 mg/m2 of docetaxel followed by 60 mg/m2 of cisplatin. This regimen was repeated at least three times at 3-week intervals. RESULTS: The overall response rate was 26.7%. The median time to disease progression was 4.5 months. The median survival time was 13 months from the start of the first-line therapy and 6 months from the second-line therapy. With respect to toxicity, the major adverse effect was leukopenia, which reached grades 3-4 in 26.7%. Non-hematological toxicities were usually moderate, and no deaths were attributable to the adverse effects of the drugs. CONCLUSION: This combination therapy was effective as a second-line treatment for advanced gastric cancer with acceptable toxic side-effects.
Authors: M Martin-Richard; R Gallego; C Pericay; J Garcia Foncillas; B Queralt; E Casado; J Barriuso; V Iranzo; I Juez; L Visa; E Saigi; A Barnadas; X Garcia-Albeniz; J Maurel Journal: Invest New Drugs Date: 2013-12 Impact factor: 3.850
Authors: Kate Crawford; Erin Bontrager; Margaret A Schwarz; Apurva Chaturvedi; Daniel D Lee; Hassan Md Sazzad; Urs von Holzen; Changhua Zhang; Roderich E Schwarz; Niranjan Awasthi Journal: Cancer Biol Ther Date: 2021-12-09 Impact factor: 4.742
Authors: Keun-Wook Lee; Bum Jun Kim; Mi-Jung Kim; Hye Sook Han; Jin Won Kim; Young Iee Park; Sook Ryun Park Journal: Cancer Res Treat Date: 2016-10-18 Impact factor: 4.679